MDLinxFDA Greenlights Amtagvi: New Hope for Treating Advanced Melanoma

Pioneering Cellular Therapy: A New Horizon in Melanoma Treatment

The FDA’s recent approval of Amtagvi (lifileucel) marks a significant milestone in the treatment of advanced melanoma, introducing the first cellular therapy for solid tumors to the medical field. This approval, based on encouraging Phase II trial results, offers new hope for patients with few alternatives, setting a precedent for future innovations in cancer therapy.

Key Points:

• The FDA has approved Amtagvi (lifileucel) for patients with unresectable or metastatic melanoma who have not responded to prior treatments, including a PD-1 blocking antibody or a BRAF inhibitor.
• Amtagvi, developed by Iovance Biotherapeutics, is the first FDA-approved cellular therapy for solid tumors, specifically targeting advanced melanoma.
• In a Phase II clinical trial, Amtagvi demonstrated a 31.5% objective response rate among 73 treated patients, with responses being durable over six, nine, and twelve months for a significant proportion of responders.
• The therapy involves extracting and expanding a patient’s own tumor-infiltrating lymphocytes (TILs), then infusing them back to attack the cancer cells, a process known as TIL-cell therapy.
• Prior to receiving Amtagvi, patients must undergo lymph-depleting chemotherapy to enhance the efficacy of the infused T cells.
• A confirmatory Phase III trial is in progress to provide additional data to potentially convert Amtagvi’s accelerated approval into full approval.
• Experts suggest that the success of Amtagvi could pave the way for TIL-cell therapies in other types of solid tumors, expanding the impact of this innovative approach.

“This is a real signal of hope. We talk about transformational versus incremental work [in medicine]. This is a transformational step. We’ve got something that has never been done before—never even gone to the FDA for approval—and never shown this kind of activity in patients.”
– Kim Margolin, MD, Medical Oncologist and Medical Director of the Melanoma Program at Saint John’s Cancer Institute in Santa Monica, CA

More on Melanoma